Daily non-political popular news in brief.

Novel therapy for lipid disorders shows mixed results in early clinical trials

03-25-2007 · EurekAlert!

Preliminary research suggests that use of a novel, potent drug to treat cholesterol disorders decreases triglycerides and increases HDL-C, the "good" cholesterol, but also raises some safety concerns, according to a study in the March 28 issue of JAMA. The study is being released early to coincide with its presentation at the American College of Cardiology's annual conference.

Keywords: novel, therapy, lipid, disorders, shows, mixed, results, clinical, trials, disorder, show, result, trial

« Previous | Next »

Similar news on "Novel therapy for lipid disorders shows mixed results in early clinical trials":

Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
01-31-2008 · EurekAlert!
Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of The Lancet.
Similar news · Read more »
Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder
01-31-2008 · EurekAlert!
Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of the Lancet.
Similar news · Read more »
Phase I study of novel gene therapy for HIV
11-06-2006 · EurekAlert!
The results are in for Phase I clinical trials of a gene therapy for AIDS. The trial was conducted at U-Penn where five patients with chronic HIV who had failed prior therapies were given a one-time infusion. They all tolerated the therapy and showed improved immune system response. This is the first publication of an effective gene therapy for AIDS to show positive clinical results in the peer review literature.
Similar news · Read more »
VEGF Trap shows activity in patients with advanced ovarian cancer
06-02-2007 · EurekAlert!
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents. The findings, which are being presented today at the American Society of Clinical Oncology’s annual meeting, may indicate a role for this targeted therapy in women with ovarian cancer who have exhausted all other options.
Similar news · Read more »
Multiple myeloma clinical trial shows distinct survival benefit with lower dose of steroids
12-09-2007 · EurekAlert!
Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported today by S. Vincent Rajkumar, MD, at the American Society of Hematology's annual meeting.
Similar news · Read more »
Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia
12-09-2007 · EurekAlert!
Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at the University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.
Similar news · Read more »
Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
03-27-2007 · EurekAlert!
Heart attacks are caused by a build-up and instability of plaque in the coronary arteries, which is often a result of chronic inflammation of the blood vessel walls. A study presented today at the American College of Cardiology's 56th Annual Scientific Session assessed whether adding a novel agent with antioxidant and anti-inflammatory properties to optimal medical therapy would reduce coronary events and death among patients with heart disease.
Similar news · Read more »
Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
11-15-2007 · EurekAlert!
Advanced Life Sciences Holdings, Inc. today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia, the sixth leading cause of death in the United States.
Similar news · Read more »
International HIV/AIDS trial finds risks increase on episodic antiretroviral therapy
11-29-2006 · EurekAlert!
Results from one of the largest HIV/AIDS treatment trials ever conducted show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause. In the study, the investigators used two predetermined levels of CD4+ T cells, the primary immune cell targeted by HIV, to guide them in respectively suspending or restarting the study participants on antiretroviral therapy.
Similar news · Read more »
Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
09-04-2007 · EurekAlert!
The results of a clinical trial, published in late August in the Journal of Pediatrics, indicates that, when used as part of routine therapy, high-dose ibuprofen is safe and effective in slowing down lung disease in children with cystic fibrosis (CF).
Similar news · Read more »